Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Long-Term Investments (2016 - 2025)

Zevra Therapeutics' Long-Term Investments history spans 5 years, with the latest figure at $47.9 million for Q4 2025.

  • For Q4 2025, Long-Term Investments rose 696.66% year-over-year to $47.9 million; the TTM value through Dec 2025 reached $47.9 million, up 696.66%, while the annual FY2025 figure was $47.9 million, 696.66% up from the prior year.
  • Long-Term Investments reached $47.9 million in Q4 2025 per ZVRA's latest filing, up from $30.9 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $47.9 million in Q4 2025 to a low of $490000.0 in Q4 2021.
  • Average Long-Term Investments over 4 years is $19.6 million, with a median of $17.6 million recorded in 2022.
  • Peak YoY movement for Long-Term Investments: surged 3981.63% in 2022, then surged 405.57% in 2025.
  • A 4-year view of Long-Term Investments shows it stood at $490000.0 in 2021, then soared by 3981.63% to $20.0 million in 2022, then crashed by 69.95% to $6.0 million in 2024, then soared by 696.66% to $47.9 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Long-Term Investments are $47.9 million (Q4 2025), $30.9 million (Q3 2025), and $15.1 million (Q2 2025).